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(I. Hamaguchi).Megakaryopoiesis is associated with inﬂammatory reactions. To investigate the role of interferon
regulatory factors (IRFs) in inﬂammation-associated megakaryopoiesis, mouse bone marrow hema-
topoietic stem cells (HSCs) were analyzed. IFN-c treatment induced IRF-2 expression as well as the
expression of CD41 and IRF-1 in HSCs. An in vitro clonogenic assay showed that IRF-2- but not IRF-1-
overexpressing cells increased the number of megakaryocytic colonies. IRF-2 transfection up-regu-
lated CD41 promoter activity in hematopoietic cell lines. The number of CD41-positive bone marrow
cells increased in mice injected with IRF-2-expressing bone marrow cells. These ﬁndings suggest
that IRF-2 plays an important role in megakaryopoiesis in inﬂammatory states.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction the transport of the antigenic peptides-1 (TAP-1) promoter, whichProinﬂammatory cytokines have a strong effect on the
hematopoietic system and can promote the expression of the
megakaryocyte lineage with subsequent thrombocytosis. While
the association between inﬂammation and thrombocytosis has
beenwell investigated, the speciﬁcmechanismbywhich inﬂamma-
tory signaling affects gene expression remains unknown. Inﬂamma-
tory cytokines, including IFN-c, have been reported to induce
megakaryocyte and platelet production [1,2]. Recently, it was
reported that interferon regulatory factor (IRF)-1 and IRF-2 are in-
volved in the activation ofmegakaryopoiesis after IFN-c stimulation
[3,4]. Huang et al. reported that the master regulator GATA-1 pro-
motes megakaryopoiesis through the activation of IFN-c/STAT-1
signaling, in which the downstream transcriptional target is IRF-1
[4]. Rouetz et al. showed that IRF-2 is a key factor that regulateschemical Societies. Published by E
SC, hematopoietic stem cell;
egakaryocyte; CFU-GM, CFU-
rescent protein; TPO, throm-
erferon-stimulated response
usashimurayama-shi, Tokyo
asumi), 130hama@nih.go.jpcorrelates with IFN-c-induced megakaryopoiesis [3].
IRF-2 has generally been described as a transcriptional repres-
sor in the interferon production system and is thought to function
by competing with IRF-1 [5]. The physiological role of IRF-2 in
lymphoid and hematopoietic development has been investigated
by the analysis of IRF-2 knockout mice, and a general bone marrow
suppression of hematopoiesis and B lymphopoiesis was shown [6].
Recently, a marked reduction in hematopoietic stem cells (HSCs) in
IRF-2 knockout mice was demonstrated in association with a type I
interferon-dependent mechanism [7]. These reports are consistent
with the function of IRF-2 as a repressor for the interferon signaling
system. However, IRF-2 is a positive regulator for the interferon-
stimulated response element (ISRE)-like sequences, such as those
found in the promoters of H4, vascular adhesion molecule-1
(VCAM-1), CIITA, gp91phox and Fas ligand [8–13]. Another report
indicated that IRF-2 drives megakaryocytic differentiation via
activation of the thrombopoietin (TPO) receptor promoter in a cell
culture system [14].
The present study provides a functional analysis of IRF-2 as a
positive regulator in mouse primary hematopoietic cells and re-
veals the role of IRF-2 in IFN-c-mediated megakaryopoiesis. This
is the ﬁrst evidence showing that IRF-2 is an important molecule
for megakaryopoiesis in bone marrow cells. During inﬂammatory
states, a special differentiation pathway mediated by factors,
including IRF-2, is active in HSCs.lsevier B.V. All rights reserved.
Fig. 1. IFN-treatment induces IRF-2 expression as well as CD41. Mouse bone marrow
cells frommice injectedwith5-FUwerecultured in thepresenceof IFN-corTPOor IFN-
c plus TPO at the indicated concentrations. RNA was isolated and real-time PCR was
performed using CD41, IRF-1, IRF-2 and b-actin-speciﬁc primers. Data are represen-
tative of three independent experiments with similar results. The relative quantity of
mRNA for each gene was quantiﬁed using the comparative Ct method (2DCt).
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2.1. Antibodies and cytokines
Rat IgG2b anti-mouse lineage markers, PE-CD41, APC-c-kit,
FITC-Sca1, APC-CD45.2 and APC-CD45.1 antibodies, were pur-
chased from eBioscience (San Diego, CA, USA). The recombinant
cytokines mouse IL-6, mouse stem cell factor (SCF), mouse IL-3,
mouse Flt3 ligand, mouse G-CSF, and human TPO were purchased
from Peprotec (Rocky Hill, NJ, USA). Mouse IFN-c was a gift from
Toray Co. (Kamakura, Japan). Anti-a-tubulin antibody was from
Sigma (St Louis, MO, USA).
2.2. Isolation of lineage and hematopoietic stem cells
Mouse HSCs were puriﬁed from the bone marrow cells of 8- to
12-week-old C57BL/6mice. In brief, low-density cells were isolated
on Histopaque (Sigma). The cells were stained with an antibody
cocktail consisting of PE (phycoerythrin)-conjugated anti-Gr-1,
Mac-1, B220, CD4, and CD8 monoclonal antibodies (BD Biosci-
ences). Lineage-positive cells were depleted with anti-PE Micro
beads (Miltenyi Biotec). The remaining lineage-depleted cells were
further stained with FITC-CD34, APC-Sca-1, and APC750-c-Kit anti-
bodies to isolate CD34-KSL. Color analysis and sorting were per-
formed using ﬂow cytometry (JSAN Bay Bioscience, Kobe, Japan).
2.3. Retrovirus production and infection of cells
cDNA fragments for mouse IRF-2, DIRF-2 and IRF-1 were
independently subcloned into a retrovirus vector, pMRIG/IRES-
enhanced green ﬂuorescent protein (EGFP) [12,15–17]. Detailed
methods are described in Supplementary data.
2.4. Construction of the lentiviral vector
IRF-2 siRNA was inserted into a lentiviral vector, and lentivirus
copies were produced as previously described [18–20]. The IRF-2
siRNA oligonucleotide sequence was GATAGAAGTATAAAGGAAT.
Non-speciﬁc control siRNA (scrambled, scr) oligonucleotides were
produced as previously described [19]
2.5. Real-time RT-PCR
Real-time RT-PCR was performed as previously described [19].
Detailed methods and primers are described in Supplementary
data.
2.6. In situ hybridization
In situ hybridization of non-decalciﬁed bone marrow cells
was carried out using digoxygenin (DIG)-labeled RNA probes as
described previously [21]. Detailed methods and primers are
described in Supplementary data.
2.7. Clonogenic progenitor assay
Detailed methods are described in Supplementary data.
2.8. Cell culture
K562 cells and mouse RAW cells were grown in RPMI 1640
medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10%
FCS, 100 lg/ml penicillin and 100 U/ml streptomycin (Sigma).
NIH3T3cells were grown in DMEM supplemented with 10% FCS.
K562 cells stably transfected with IRF-2 were produced as previ-ously described [22]. UT7/TPO cells were grown in IMDM medium
supplemented with 10% FCS and 10 ng/ml TPO.
2.9. Bead assay and Western blotting
The bead assay and Western blotting were performed as previ-
ously described [22]. Detailed methods and primers are described
in Supplementary data.
2.10. Luciferase reporter assay
Detailed methods are described in Supplementary data.
2.11. Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed as previously
described [22]. Detailed methods and primers are described in
Supplementary data.
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Bone marrow cells isolated from 5-ﬂuorouracil (5-FU)-injected
mice (C57BL/6-Ly5.1) were cultured in a-MEM containing 20% fe-
tal calf serum with mIL-6 (50 ng/ml) and mSCF (100 ng/ml) for
2 days and then infected with GFP or IRF-2/GFP retrovirus. After
3 days, 1  105 to 5  105 cells, including GFP-positive and GFP-
negative cells, were injected into irradiated (9.5 Gy) C57BL/6-
Ly5.2 mice with 1  106 competitor cells from C57BL/6-Ly5.2 bone
marrow cells. Five weeks after transplantation, isolated bone mar-
row cells were stained with PE-conjugated CD41 antibody. The ra-
tio of CD41-positive cells to GFP-positive cells was analyzed.
3. Results
3.1. IFN-c induces IRF-2 and CD41 expression in mouse bone marrow
stem/progenitor cells
To investigate megakaryopoiesis in mouse bone marrow cells in
an inﬂammatory state, bone marrow cells from 5-FU-injected mice
were treated with IFN-c. Three days after treatment, real-time PCR
analysis revealed that IFN-c treatment induced CD41 expression
comparable to TPO treatment (Fig. 1). Next, the IRF-1 and IRF-2
expression levels were analyzed after treatment with IFN-c. Inter-Fig. 2. IRF-2 exists in bone marrow stem cells. (A) RNA was isolated from Gr1/Mac1, B22
using a cell sorter. Real-time PCR was performed using IRF-1- and IRF-2-speciﬁc primers
IRF-2 (a and c) and IRF-1 (b and d) in mouse bone marrow by in situ hybridization anaestingly, IRF-2 expression was increased by around 80–100%. But
its induction level was much lower than that of IRF-1 (Fig. 1).
TPO treatment did not increase IRF expression, nor did it enhance
the IFN-c-induced IRF expression level, indicating that the effects
of TPO and IFN-c occur via different pathways (Fig. 1). There was
no change of IRFs expression in bone marrow stem/progenitor cells
after treatment with TPO, indicating that IRFs expression did not
change during normal megakaryocytic differentiation.
3.2. IRF-2 is expressed in hematopoietic stem cells
To analyze the expression of IRFs in mouse bone marrow cells,
Gr1/Mac1-positive, B220-positive, Ter119-positive/lineage (Lin)
negative and KSL (c-kit+Sca-1+Lin-) cells were isolated frommouse
bone marrow cells by ﬂow cytometry, and then real-time PCR was
performed. Interestingly, the IRF-2 expression level was substan-
tially high in the CD34-KSL (HSC) fraction compared with other
lineage fractions (Fig. 2A). The IRF-1 expression level was also high
in the CD34-KSL fraction, but the relative expression level of IRF-2
was much higher than that of IRF-1 in stem cells (Fig. 2A). In situ
hybridization showed that IRF-2-expressing cells were detected,
particularly in the endosteal region of the trabecular bone. On
the other hand, IRF-1-expressing cells were widely distributed in
the bone marrow (Fig. 2B).0, Ter119, Lin-, CD34+KSL and CD34-KSL cells fractionated from bone marrow cells
. The expression ratio of each gene to b-actin is indicated. (B) Expression patterns of
lysis. TB: trabecular bone. Bar: 20 lm.
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The direct function of IRF-1 and IRF-2 in HSCs was investigated.
As shown in Fig. 3A, the cDNAs for IRF-1 and IRF-2 were inserted
into pMSCV-IRES-EGFP retrovirus vectors and transfected into
packaging cells to produce retroviral supernatants. Each retrovi-
ruses were conﬁrmed to induce the protein expression in NIH3T3
cells (Fig. 3A). Mouse bone marrow cells transfected with GFP-,
IRF-2-, or IRF-1-expressing retroviruses showed 42.0%, 35.0% and
43.0% GFP-positive cells, respectively. We used the separatedFig. 3. Transduction of IRFs into hematopoietic stem/progenitor cells. (A) Retrovirus co
Schematic of the control vector, pMSCV, and the bicistronic vector containing the IRF-2, IR
(GFP). LTR: long terminal repeat; IRES: internal ribosomal entry site. Nuclear protein (20 l
GFP (lanes 1 and 5), IRF-2-GFP (lane 2), DIRF-2-GFP (lane 3) or IRF-1-GFP (lane 4) was ele
and 5) and anti-a-tubulin antibodies (lanes 1–5) was performed. (B) The population of
DIRF-2-GFP or IRF-1-GFP. (C) The GFP-positive fractions, indicated as R in (B), were isolate
2. Values represent the mean ± S.D. of triplicate cultures in a representative experim
differences (P < 0.05) were determined using Student’s t-test.GFP-positive cells for colony assays (Fig. 3B). For the colony form-
ing unit-megakaryocyte (CFU-Mk) assay, the megakaryocyte col-
ony number signiﬁcantly increased by around 80–100% in IRF-2
retrovirus-infected cells, but the megakaryocyte colony number
of IRF-1 retrovirus-transduced cells did not change (Fig. 3C left;
5.5 ± 1.3, 10.3 ± 3.2 and 5.7 ± 0.6). Neither IRF-2 nor IRF-1 changed
the colony numbers in the CFU-granulocyte/macrophage (CFU-
GM) assay compared with the GFP control (GFP: 21.7 ± 1.0, IRF-2:
19.7 ± 0.6 and IRF-1: 21.0 ± 1.8). IRF-2 is a transcription factor that
has a DNA binding domain in the N-terminal region that binds tonstructs for mouse IRF-1, IRF-2 and DIRF-2 which lacks the DNA binding domain.
F-1 and DIRF-2 cDNAs. Both vectors contain the enhanced green ﬂuorescent protein
g protein) in GFP-positive cells from NIH 3T3 cells infected with retrovirus encoding
ctrophoresed. Immunoblot analysis using anti-IRF-2 (lanes 1–3), anti-IRF-1 (lanes 4
GFP-positive cells from MN cells infected with retrovirus encoding GFP, IRF-2-GFP,
d and then CFU-GM and CFU-Mk assays were performed as described under Section
ent. Similar results were obtained in three independent experiments. Signiﬁcant
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which lacks the DNA binding domain, was also inserted into a ret-
rovirus vector as a control. The DIRF-2-GFP cassette-containing
retrovirus was used to infect mononuclear cells (MN cells) isolated
from 5-FU-treated mice, and 65.2% of the cells were found to be
GFP-positive and were separated by ﬂow cytometry (Fig. 3B). The
DIRF-2 mutant did not change the megakaryocytic or GM colony
numbers (Fig. 3C; 5.6 ± 0.4 for megakaryocyte colonies, 21.7 ± 2.1
for GM colonies) (Fig. 3C). These results indicated that the forced
expression of IRF-2 led to an induction of megakaryocytic differen-
tiation in mouse bone marrow stem cells and that the DNA binding
site in IRF-2 was important for this induction. When megakaryo-
cyte differentiation marker, CD41 protein expression level was
analyzed by ﬂow cytometry, higher population of CD41-positive
cells was detected in IRF-2-transduced cells compared to all other
types of transduced cells (Fig. 3D). To determine whether
decreased IRF-2 expression also modiﬁed mouse hematopoiesis, a
pLV-TH/siRNA lentiviral vector was modiﬁed with a siRNAIRF-2
oligonucleotide and results (Fig. 4A–D) were described in
supplementary results. These results indicated that the decreased
expression level of IRF-2 protein led to the reduction of megak-
aryocyte-committed progenitors.
3.4. Forced IRF-2 expression induces CD41 expression in vivo
Furthermore, we investigated whether IRF-2 enhances CD41
expression in vivo. 5-FU-treated mouse bone marrow cells were in-
fected with the IRF-2-GFP retrovirus. For transplantation analysis,
both GFP-positive and GFP-negative cells were injected into
X-ray-irradiated mice (Fig. 5A). Five weeks after transplantation,
the proportion of CD41-positive per GFP-positive cells in the bone
marrow cells from recipient mice was analyzed by ﬂow cytometry.
GFP+CD45.1+ cells amounted to 8.0% and 3.0% in GFP- and IRF-2-Fig. 4. Decreased IRF-2 expression levels impair murine adult hematopoiesis. (A) Len
inactivating long terminal repeat; cPPT: central polypurine tract; WPRE: woodchuck hepa
in shRNA control and shRNAIRF-2-transduced RAW cells. (C) The population of GFP-pos
positive cells were isolated from R in (C), and then CFU-GM and CFU-Mk assays were pe
cultures in a representative experiment. The data are representative of three independent
using Student’s t-test.GFP-expressing bone marrow cells, respectively (Fig. 5B left).
Forced IRF-2 expression in bone marrow cells enhanced the pro-
portion of CD41-positive cells in the bone marrow compared with
the control (Fig. 5B right; 8.4 ± 4.6% and 23.7 ± 14.8% from 6 and 5
mice, respectively). These observations conclusively showed that
IRF-2 induces CD41-positive cell-expression of murine HSCs.
Next, we examined the megakaryopoiesis-speciﬁc gene expres-
sion in bone marrow cells. IRF-1, 2 and IRF-2DBD mutants were
transduced into bone marrow cells from 5-FU-treated mice. After
3 days of culture, RNA from the GFP-positive cells was isolated
and real-time PCR was performed. As shown in Fig. 5C, IRF-2 trans-
duction enhanced PF4, GATA-1 and CD41 expression compared
with GFP transduction alone. However, IRF-2DBD mutant- and
IRF-1-transduced cells did not change the expression of these
genes. We demonstrated that IRF-2 activated CD41, together with
another hematopoietic speciﬁc factor, PF4, and GATA-1.
3.5. IRF-2 transactivates the CD41 promoter
To investigate whether IRF-2 induces the promoter activity of
the genes responsible for megakaryocytic differentiation, the pro-
moter regions from several hematopoietic factors, such as mpl,
CD41, GATA-1, GATA-2, globin genes, Tal1 and NF-E2, were exam-
ined for ISRE-like sequences using TFSEARCH. TFSEARCH indicated
that binding sites with a high afﬁnity for IRF-2 exist in the CD41
promoter. To conﬁrm the IRF-2 binding activity to the CD41 pro-
moter, a bead assay was performed using both human and mouse
CD41 promoter oligonucleotides with an IRF-2-expressing nuclear
extract. We used the Qp promoter from the EBV latency promoter,
which includes ISRE [23] as a positive control. IRF-2 binds to the Qp
wild type promoter, but not to the mutant Qp, as reported previ-
ously [23]. IRF-2 bands were observed in human CD41 (hCD41)
and mouse CD41 (mCD41) promoter oligonucleotide boundtiviral construct for murine IRF-2shRNA. EF1-a: elongation factor-1-a; SIN: self-
titis virus post-transcriptional regulatory element. (B) Western blot analysis of IRF-2
itive cells from lentiviral-transduced cells. R indicates GFP-positive cells. (D) GFP-
rformed as described under Section 2. Values represent the mean ± S.D. of triplicate
experiments with similar results. Signiﬁcant differences (P < 0.05) were determined
Fig. 5. Analysis of CD41-positive cells in transplanted mice. (A) Experimental scheme used for transplantation. (B) All cells, including GFP-positive and GFP-negative cells,
were transplanted into X-ray-irradiated mice. Five weeks after transplantation, bone marrow cells were isolated from the recipient mice, and the ratio of CD41-positive cells
to GFP-positive cells was analyzed by ﬂow cytometry. Signiﬁcant differences (P < 0.05) were determined using Student’s t-test. (C) Enhanced gene expression in IRF-2-
expressing stem/progenitor cells. Bone marrow cells were isolated frommice injected with 5-FU, and the cells were infected with retrovirus encoding GFP, IRF-2-GFP,DIRF-2-
GFP or IRF-1-GFP. After 3 days of culture, GFP-positive cells were isolated by cell sorting and RNA was isolated. Real-time PCR was performed using primers speciﬁc for PF4,
NF-E2, MPL, GATA-1 and GATA-2 cDNA. Data are representative of three independent experiments with similar results. Data were normalized to the expression of GAPDH and
are expressed as the relative mRNA expression levels (2DCt).
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Qp positive control (Fig. 6A). Free CD41 double-stranded oligonu-
cleotides abrogated this binding completely, indicating the speci-
ﬁcity of IRF-2 binding to the promoter. IRF-2 binding sites could
not be found for other hematopoietic factors, such as mpl, GATAs,
Tal1 and NF-E2 (data not shown). Chromatin immunoprecipitation
analysis (Fig. 6B) and reporter analysis (Fig. 6C and D) were de-
scribed in supplementary results. Based on the results of these re-
porter assays, we demonstrated that IRF-2 is a positive regulator of
CD41 expression.
4. Discussion
In the present study, we demonstrated that IRF-2 is present at
relatively high levels in mouse bone marrow HSCs. IRF-1 was alsopresent at high levels in KSL cells, but IRF-2 was localized in partic-
ular to the CD34-KSL fraction. Investigation of the function of IRF-2
in mouse bone marrow stem cells contributes to the elucidation of
the novel mechanism of the hematopoietic system. The present
study found that IRF-2 expression increased after treatment with
IFN-c in bone marrow cells from 5-FU-injected mice. IRF-2 expres-
sion clearly induced megakaryocyte development of primary HSCs
together with the response to IFN-c. IRF-2-forced expression and
IRF-2 knockdown experiments provided direct evidence that IRF-
2 is necessary for megakaryocytic differentiation from HSCs.
The platelet glycoprotein receptors CD42b/CD42a and CD41/
CD61 are involved in megakaryocyte-speciﬁc genes [24]. CD41 is
a megakaryocyte-speciﬁc gene and is associated with megakaryo-
poiesis [25,26]. Among several hematopoietic factors, IRF-2 bound
to both human and mouse CD41 promoter ISRE-like sequences.
Fig. 6. IRF-2 binds to the CD41 promoter. (A) Beads conjugated to oligonucleotides were incubated with nuclear extracts prepared from IRF-2-expressing K562 cells. The
eluted fraction from the magnetic beads was subjected to SDS-10% PAGE and immunoblotted with an IRF-2 antibody. The ISRE-like site in the CD41 promoter is underlined.
(B) Chromatin immunoprecipitation (ChIP) analysis of the CD41 promoter. IRF-2 stably transfected K562 cells were subjected to ChIP analysis with anti-IRF-2 antibody (lanes
2 and 3) and rabbit IgG antibody (lanes 4 and 5). Aliquots of 5 ll (lanes 2 and 4) and 10 ll (lanes 3 and 5) from the eluted DNA fractions were used for PCR. A sample
containing 5% of the total input chromatin was also included in the ChIP assay (lane 1). Similar ChIP experiments using the GAPDH promoter region were also included as a
control. (C) IRF-2 activates the mouse CD41 promoter in K562 and UT7/TPO cells. Nuclear extract (30 lg protein) from both K562 and UT7/TPO cells analyzed by Western
blotting using anti-IRF-2 antibody (upper panel). The mouse CD41 reporter construct was transfected with IRF-2pcDNA3.1 into K562 and UT7/TPO cells. Twenty-four hours
after transfection, the luciferase activity was analyzed (lower panel). (D) Mutation of the ISRE-like site in the mouse CD41 promoter reduced the level of activation by IRF-2.
Wild-type CD41 and mutant CD41 reporters were transfected with IRF-2pcDNA3.1, and the luciferase activity was analyzed 24 h after transfection. Wild-type and mutant
ISRE-like sites in the CD41 reporter are underlined. Relative promoter activity for each construct to empty vector control was shown.
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poietic factors (data not shown). An in vitro reporter assay showed
that IRF-2 was a positive regulator of the CD41 promoter. IRF-2
also induced CD41 expression in vivo in a transplantation analysis.
Thus, the present results are the ﬁrst evidence showing that IRF-2
regulates the hematopoietic differentiation marker CD41. In eluci-
dating the mechanism of IRF-2-mediated megakaryopoiesis, the
involvement of other megakaryocyte-speciﬁc factors cannot be
excluded. Megakaryocyte development is controlled by lineage-
speciﬁc transcription factors, such as Tal1, GATA-1, FOG-1 (Friend
of GATA-1), NF-E2 and GATA-2 [24,27–30]. Under steady-state
conditions, these transcription factors are required for the mainte-
nance of HSCs, and a deﬁciency of these genes has shed light on the
transcriptional regulation of megakaryopoiesis. Tal1 or GATA-2
exists at high levels in mouse HSCs and are necessary for hemato-
poietic differentiation [31,32]. However, whether these transcrip-
tion factors regulate CD41 directly has not been demonstrated.
IRF-2 acts as an inducer for megakaryocytic development via amechanism that is distinct from that of other lineage-speciﬁc
transcription factors. IRF-2 may not control megakaryocyte devel-
opment under steady-state conditions; however, under an inﬂam-
matory state, IRF-2 is up-regulated and begins to activate
megakaryocyte differentiation. Real-time PCR analysis indicated
that IRF-2 transduction induced the expression of the megakaryo-
cyte maturation marker genes PF4, GATA-1, CD41 not NF-E2,
GATA-2 and MPL. PF4 and GATA-1 may be enhanced following
the activation of CD41 mediated by IRF-2.
The response of IRF-1 to IFN-c stimulation is much stronger
than that of IRF-2. However, the present study could not conﬁrm
a megakaryopoietic effect from the forced expression of IRF-1 in
the present megakaryocytic colony assay and real-time PCR analy-
sis. IRF-1 may play a different role in megakaryocytic differentia-
tion by cooperating with other transcription factors, including
IRF-2. IRF-2 represses IFN-inducible genes, including IRF-1, but it
also synergizes with IRF-1 depending on the target [33]. IFN-c
stimulation may affect IRF-2-mediated CD41 enhancement by
3500 A. Masumi et al. / FEBS Letters 583 (2009) 3493–3500competing or cooperating with IFN-c-inducedmediators, including
IRF-1. The role of IRF-2 in megakaryopoiesis may differ from that of
IRF-1. Further investigation is required regarding the mechanism
of the association of inﬂammatory disorders with IRF-2.
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